Information Provided By:
Fly News Breaks for January 9, 2020
Jan 9, 2020 | 09:05 EDT
Lake Street analyst Brooks O'Neil initiated coverage of iCAD with a Buy rating and $14 price target. The company has arrived at the "critical junction" of cancer detection and treatment at a "perfect time" to capitalize on its "unique capabilities and experienced management," O'Neil tells investors in a research note. The analyst believes iCAD offers "disruptive solutions" which deliver "significant" clinical benefits and cost savings at a time when all constituents in the health care marketplace are "loudly demanding these features."
News For ICAD From the Last 2 Days
There are no results for your query ICAD